Media › Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Companys Transformation and Progress
 
 

Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Companys Transformation and Progress

2025-04-21 15:45:03| Spiritual Career Counseling

April 07, 2025 08:00 ET | Source: Opus Genetics, Inc. Board Comments on Misguided Campaign from Mina Sooch to Replace a Majority of Opus Directors and Promote a Flawed Strategy Urges Stockholders to Vote on the BLUE Proxy Card FOR All Nine of the Companys Nominees RESEARCH TRIANGLE PARK, N.C., April 07, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Opus or the Company) (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced through a letter to Opus stockholders that it has mailed definitive proxy materials to stockholders in connection with the Companys upcoming 2025 Annual Meeting of Stockholders (the Annual Meeting), scheduled to be held on April 30, 2025. Opus stockholders of record at the close of business on March 24, 2025 are eligible to vote at the Annual Meeting. The Opus board of directors encourages stockholders to vo...


Category: Employment

 

Latest from this category

All news
»
13.12Salah's farewell? If this was his final Liverpool chapter, he delivered a fitting end
13.12Blackhawks recall Lardis following Bedard injury
13.12Hawks' Young should return to practice next week
13.12Cowboys keep CB Diggs on IR for Vikings game
13.12Source: U-M launches athletic department query
13.12Live updates from NBA Cup semifinals between Magic-Knicks, Spurs-Thunder in Vegas
13.12Follow live: Army, Navy vie for Commander-In-Chief's Trophy as rivals meet in Baltimore
13.12Salah makes EPL history on Liverpool return
More »